Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

Recruiting now · Phase 1

Conditions studied: Metastases

In brief

A prospective, interventional study evaluating the safety of Y-90 TARE for tumor control of the right side and induction of left liver hypertrophy as part of a planned single-stage or two-stage hepatectomy for patients with CLM and insufficient FLR at the time of presentation.

Key facts

Study ID

NCT05195710

Run by

M.D. Anderson Cancer Center

People needed

50

Starts

2022-11-16

Expected to finish

2028-03-31

Last updated by the study team

2026-05-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Borderline resectable unresectable (due to insufficient liver volume at presentation) colorectal liver metastases with potential curative intent, as determined by the surgeon and multidisciplinary team
• Anticipated standardized FLR (sFLR) that would require right portal vein embolization (PVE) to increase the sFLR prior to either a single major hepatectomy, or prior to the second stage hepatectomy as part of a two-stage hepatectomy strategy, all in the setting of curative-intent resection(s). This evaluation will be documented in the clinical chart
• Received at least four cycles (or two months) of chemotherapy
• Willing, able and mentally competent to provide written informed consent
• Medically and physically operable as determined by the surgeon

You may not qualify if…

• Extrahepatic disease that precludes intended curative intent treatment sequencing (treatable primary tumor and lung metastases allowed). "Treatable" is defined as having an intended future plan for local therapy (surgery, radiation, or ablation) as determined by the patient's medical oncologist and surgical oncologist
• Projected sFLR before Y-90 of <20% (starting with sFLR that is unrealistic for improvement to ≥30%)
• Performance status limitations (Karnofsky <80%, ECOG >1)
• Portal hypertension and/or cirrhosis
• Starting total bilirubin >1.3 mg/dL (except if patient has Gilbert's Disease)
• CEA >200 after 4 cycles of chemotherapy upon restaging visit
• Clinical progression of disease on imaging and/or tumor marker after 4 cycles of chemotherapy that is clinically judged by surgical oncology and medical oncology to preclude surgical resection
• Platelet count <100,000/µL
• Albumin <3.5 g/dl
• Symptomatic primary colon or rectal cancer (without pre-existing proximal diverting ostomy)
• Pregnant or breast-feeding patient
• Other medical or clinical contraindications to liver surgery
• Non-English-speaking participants

Where it is running

• M D Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.